Search Results Search Sort by RelevanceMost Recent Case and Commentary May 2019 How Should Physicians Respond to Requests for LVAD Removal? Larry A. Allen, MD, MHS Patients have a right to decline or withdraw LVADs. Informed consent and shared decision making is not easy, however, with treatments that are high risk, high reward. AMA J Ethics. 2019;21(5):E394-400. doi: 10.1001/amajethics.2019.394. Case and Commentary Oct 2019 How Should a Physician Respond to a Patient’s Pain When New Opioid Prescribing Laws Limit Shared Decision Making? Alexander J. Hjelmaas, MD and Christian J. Vercler, MD, MA Regulations’ negative influence on patient-physician relationships can be mitigated by innovation in decision science. AMA J Ethics. 2019;21(10):E838-843. doi: 10.1001/amajethics.2019.838. Letter to the Editor Oct 2019 Response to “Will We Code for Default ECMO?”: Clarifying the Scope of Do-Not-ECMO Orders Jacob A. Blythe, MA, Sarah E. Wieten, PhD, and Jason N. Batten, MD, MA The authors further consider the merits of preventing ECMO from becoming a default treatment. AMA J Ethics. 2019;21(10):E926-929. doi: 10.1001/amajethics.2019.926. Case and Commentary Nov 2019 In Experimental Hand Transplantation, Whose Views About Outcomes Should Matter Most? Andrea DiMartini, MD and Mary Amanda Dew, PhD Clinician-researchers deeply invested in data gathering are still obliged to respect a patient-subject’s right to stop being in research. AMA J Ethics. 2019;21(11):E936-942. doi: 10.1001/amajethics.2019.936. Case and Commentary Nov 2019 Should a Caregiver’s QoL Be Considered in Decisions About Whether a Patient Has an Experimental Double-Hand Transplant? Miguel I. Dorante, MD, MBE, Elaine Devine, MSW, LICSW, and Simon G. Talbot, MD Success depends on strong support, rehabilitation, adherence, and social integration. AMA J Ethics. 2019;21(11):E943-952. doi: 10.1001/amajethics.2019.943. Case and Commentary Dec 2019 Using the 4-S Framework to Guide Conversations With Patients About CRISPR Lisa S. Lehmann, MD, PhD, MSc Empathic communication skills help motivate understanding of safety, significance of harms, impact on succeeding generations, and social consequences. AMA J Ethics. 2019;21(12):E1029-1035. doi: 10.1001/amajethics.2019.1029. Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036. State of the Art and Science Feb 2017 Reasonableness, Credibility, and Clinical Disagreement Mary Jean Walker, PhD and Wendy A. Rogers, BMBS, PhD When is a source credible and how do beliefs about a source’s credibility influence assessments of evidence? AMA J Ethics. 2017;19(2):176-182. doi: 10.1001/journalofethics.2017.19.2.stas1-1702. Case and Commentary Jun 2019 Does a Patient’s Trauma History Ethically Justify a Discriminatory Clinical Referral? John R. Stone, MD, PhD A “simplicity strategy” suggests expressing respect for persons and empathy and models inclusive group inquiry, epistemic humility, and justice. AMA J Ethics. 2019;21(6):E493-498. doi: 10.1001/amajethics.2019.493. State of the Art and Science Aug 2019 Evolving Medicaid Coverage Policy and Rebates Jennifer A. Ohn, MPH and Anna Kaltenboeck, MA Ethics questions arise about the usefulness of a system that pegs Medicaid drug spending to net prices negotiated by others in the market. AMA J Ethics. 2019;21(8):E645-653. doi: 10.1001/amajethics.2019.645. Pagination First page « First Previous page ‹ Previous … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page Next › Last page Last »
Case and Commentary May 2019 How Should Physicians Respond to Requests for LVAD Removal? Larry A. Allen, MD, MHS Patients have a right to decline or withdraw LVADs. Informed consent and shared decision making is not easy, however, with treatments that are high risk, high reward. AMA J Ethics. 2019;21(5):E394-400. doi: 10.1001/amajethics.2019.394.
Case and Commentary Oct 2019 How Should a Physician Respond to a Patient’s Pain When New Opioid Prescribing Laws Limit Shared Decision Making? Alexander J. Hjelmaas, MD and Christian J. Vercler, MD, MA Regulations’ negative influence on patient-physician relationships can be mitigated by innovation in decision science. AMA J Ethics. 2019;21(10):E838-843. doi: 10.1001/amajethics.2019.838.
Letter to the Editor Oct 2019 Response to “Will We Code for Default ECMO?”: Clarifying the Scope of Do-Not-ECMO Orders Jacob A. Blythe, MA, Sarah E. Wieten, PhD, and Jason N. Batten, MD, MA The authors further consider the merits of preventing ECMO from becoming a default treatment. AMA J Ethics. 2019;21(10):E926-929. doi: 10.1001/amajethics.2019.926.
Case and Commentary Nov 2019 In Experimental Hand Transplantation, Whose Views About Outcomes Should Matter Most? Andrea DiMartini, MD and Mary Amanda Dew, PhD Clinician-researchers deeply invested in data gathering are still obliged to respect a patient-subject’s right to stop being in research. AMA J Ethics. 2019;21(11):E936-942. doi: 10.1001/amajethics.2019.936.
Case and Commentary Nov 2019 Should a Caregiver’s QoL Be Considered in Decisions About Whether a Patient Has an Experimental Double-Hand Transplant? Miguel I. Dorante, MD, MBE, Elaine Devine, MSW, LICSW, and Simon G. Talbot, MD Success depends on strong support, rehabilitation, adherence, and social integration. AMA J Ethics. 2019;21(11):E943-952. doi: 10.1001/amajethics.2019.943.
Case and Commentary Dec 2019 Using the 4-S Framework to Guide Conversations With Patients About CRISPR Lisa S. Lehmann, MD, PhD, MSc Empathic communication skills help motivate understanding of safety, significance of harms, impact on succeeding generations, and social consequences. AMA J Ethics. 2019;21(12):E1029-1035. doi: 10.1001/amajethics.2019.1029.
Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036.
State of the Art and Science Feb 2017 Reasonableness, Credibility, and Clinical Disagreement Mary Jean Walker, PhD and Wendy A. Rogers, BMBS, PhD When is a source credible and how do beliefs about a source’s credibility influence assessments of evidence? AMA J Ethics. 2017;19(2):176-182. doi: 10.1001/journalofethics.2017.19.2.stas1-1702.
Case and Commentary Jun 2019 Does a Patient’s Trauma History Ethically Justify a Discriminatory Clinical Referral? John R. Stone, MD, PhD A “simplicity strategy” suggests expressing respect for persons and empathy and models inclusive group inquiry, epistemic humility, and justice. AMA J Ethics. 2019;21(6):E493-498. doi: 10.1001/amajethics.2019.493.
State of the Art and Science Aug 2019 Evolving Medicaid Coverage Policy and Rebates Jennifer A. Ohn, MPH and Anna Kaltenboeck, MA Ethics questions arise about the usefulness of a system that pegs Medicaid drug spending to net prices negotiated by others in the market. AMA J Ethics. 2019;21(8):E645-653. doi: 10.1001/amajethics.2019.645.